1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Jubilant Pharmova Limited

Jubilant Pharmova Limited

JUBLPHARMA.NS
Jubilant Pharmova LimitedIN flagNational Stock Exchange of India
967.75
INR
+3.55
- -
153.28BMarket Cap
Jubilant Pharmova Limited
JUBLPHARMA.NS
(National Stock Exchange of India)

Recent

price

967.75

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
2,163.23
267.07
320.99
359.21
362.64
361.66
369.88
476.43
577.24
366.83
374.46
380.66
390.79
419.21
454.03
- -
463.74
Revenue per Share
144.22
0.91
9.59
6.85
-3.63
25.1
36.93
41.25
36.86
56.39
52.48
26.01
-3.83
4.86
52.99
- -
29.03
Basic EPS, GAAP
-120.35
5.81
60.89
48.48
49.17
70.38
81.38
83.62
71.95
60.82
78.91
14.92
-9.66
4.64
-2.75
- -
- -
Free Cash Flow per Basic Share
23.17
2.31
3.44
3.47
3.38
3.56
3.58
3.6
3.5
9.59
0.09
5.03
5.03
5.03
5.03
- -
- -
Dividend per Share
591.84
56.29
61.55
65.3
80.11
104.54
135.34
170.38
200.08
242.39
272.1
295.33
286.07
287.4
335.69
- -
- -
Book Value per Share
176.82
18.59
28.35
27.93
10.7
30.36
58.56
93.43
137.75
174.73
113.71
134.9
126.44
120.75
164.19
- -
- -
Tangible Book Value per Share
16
159
159
159
159
156
156
156
156
159
159
159
159
159
158
- -
159
Basic Weighted Avg Shares
34,456
42,539
51,128
57,216
57,761
56,469
57,653
74,248
89,971
58,428
59,639
60,592
62,193
66,448
71,921
82,250
73,506
Sales/Revenue/Turnover
11.77
15.7
15.72
12.72
6.97
16.68
18.62
14.92
15.36
20.68
18.76
13.61
3.7
7.87
11.19
9.96
11.37
Operating Margin (%)
1,929
2,207
2,538
2,812
2,880
3,467
2,914
4,150
3,709
4,619
4,516
3,817
5,540
3,819
3,686
4,404
3,760
Depreciation Expense
2,297
146
1,527
1,090
-578
3,918
5,757
6,428
5,745
8,982
8,359
4,139
-610
771
8,394
3,985
4,602
Net Income, GAAP
5.56
59.96
44.66
33.6
199.59
28.66
22.1
26.15
36.16
33.08
34.12
34.49
333.45
57.36
14.72
35.27
28.07
Effective Tax Rate (%)
6.67
0.34
2.99
1.91
-1
6.94
9.98
8.66
6.38
15.37
14.02
6.83
-0.98
1.16
11.67
4.84
6.26
Profit Margin (%)
3,221
845
-2,173
-9,664
6,173
4,109
12,641
11,851
24,951
24,193
19,037
19,176
19,900
19,871
14,126
15,704
- -
Working Capital
28,365
28,399
24,688
17,169
36,615
30,132
35,050
30,478
42,429
38,758
27,594
26,764
33,237
33,649
23,888
32,999
- -
LT Debt
22,141
23,260
25,877
27,844
24,926
29,281
33,887
40,350
48,090
56,039
47,415
53,164
53,918
54,211
62,386
70,956
- -
Total Equity
6.75
4.43
6.87
6.92
-5.55
9.08
11.14
10.86
10.24
8.02
8.15
6.7
-6.1
2.46
7.64
5.4
- -
Return on Invested Capital (%)
7.37
1.52
5.42
5.19
-6.89
10.49
13.3
13.9
10.03
12.32
12
6.71
-5.59
2.32
12.9
9.2
27.88
Return on Capital (%)
24.08
1.58
16.27
10.79
-4.99
26.95
30.77
26.98
19.9
25.74
20.4
9.16
-1.32
1.69
17
14.94
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
ST Debt
- -
3,422
- -
LT Borrowings
- -
21,503
- -
LT Finance Leases
- -
2,385
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
158
- -
Market Capitalization
175,234
141,967
191,888

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
Total Current Assets
- -
35,772
- -
Cash, Cash Equivalents & STI
- -
10,986
- -
Accounts Receivable, Net
- -
8,915
- -
Inventories
- -
11,292
- -
Total Current Liabilities
- -
21,646
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
3,422
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.8%
8.58%
13.74%
Free Cash Flow
-12.14%
-28.35%
411.03%
Net Income, GAAP
64.2%
108.92%
-52.53%
Sales/Revenue/Turnover
5.28%
6.74%
14.36%
Total Cash Common Dividend
540.59%
1,065.33%
-0.13%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
15,665
16,667
16,652
17,464
66,448
2025
17,204
17,422
18,137
19,158
71,921
2026
18,789
21,161
22,722
- -
82,250

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.4
3.94
4.22
- -
4.86
2025
30.44
6.47
6.37
9.71
52.99
2026
6.49
3.52
7.55
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
5.03
2025
- -
- -
- -
- -
5.03
2026
- -
- -
- -
- -
- -
Similar Companies
High Sierra Technologies, Inc. (HSTI)
Medicine Man Technologies, Inc. (SHWZ)
Dermapharm Holding SE (52D0.F)
SES Solar Inc. (SESI)
Fagron N.V. (FAGR.BR)
SAMSUNG PHARM. Co., Ltd. (001360.KS)
Business
Jubilant Pharmova Limited Jubilant Pharmova Limited is a global integrated pharmaceutical company focused on research, development, manufacturing, and distribution of specialty products across radiopharmaceuticals, allergy immunotherapy, sterile injectables contract development and manufacturing, generics, active pharmaceutical ingredients, and proprietary novel drugs. The company manufactures and supplies radiopharmaceuticals through a network of 46 radiopharmacies primarily in the US; provides over 200 allergenic extracts, venom products, and standard allergy vaccines for markets including the US, Canada, Europe, and Australia; offers contract manufacturing services for sterile fill-and-finish injectables including liquids, lyophilization, biologics, suspensions, ophthalmics, ointments, creams, ampoules, and non-sterile products at facilities in Spokane, Washington, and Montreal, Quebec; delivers contract research and development services via centers in Bengaluru, Noida, India, and Saint-Julien-en-Genevois, France, alongside active pharmaceutical ingredient production; develops generics in solid dosage forms; and advances proprietary novel drugs through Jubilant Therapeutics targeting oncology and autoimmune disorders such as essential thrombocythemia and non-small cell lung cancer. Operations span North America, Europe, India, and other regions with six manufacturing facilities serving regulated markets including the US, Europe, Canada, Japan, and Brazil; the company, founded in 1978 and headquartered in Noida, India, employs over 5,500 people worldwide. Recent developments include the launch of a third sterile fill-and-finish line at the Spokane facility with US$132 million investment, initiating revenue from technology transfers and positioning for full utilization within three years amid strong demand from large pharma for US-based capacity; a strategic partnership with Pierre Fabre SA via subsidiary Jubilant Biosys to acquire 80% of a new French entity incorporating its R&D center, enhancing biologics and antibody-drug conjugate capabilities; completion of the API business sale to Jubilant Biosys Limited for integrated CRDMO efficiency; commercial distribution of PYLARIFY from PET radiopharmacies; and progress in Phase II and Phase I clinical trials for JBI-802 and JBI-778, respectively.